|
596
|
| 3145 |
Pilocarpine
|
|
decreases_quantity of
|
Noradrenaline
|
in all stages of status epilepticus in pilocarpine model
|
|
8112229
|
Status epilepticus
|
|
2,109
|
| 17229 |
Autism
|
NOT |
affects_quantity of
|
Noradrenaline
|
|
|
10693155
|
Autism
|
|
2,167
|
| 18145 |
Fosinoprilat
|
|
increases_quantity of
|
Noradrenaline
|
in cardiac muscle
|
|
11593103
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,183
|
| 18287 |
Noradrenaline
|
|
increases_activity of
|
vascular smooth muscle contraction
|
|
| 18288 |
Insulin
|
|
decreases_activity of
|
Noradrenaline
|
|
| 18289 |
Insulin
|
NOT |
decreases_activity of
|
Noradrenaline
|
in SHR rats
|
|
15792994
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,119
|
| 28646 |
LEP
|
|
decreases_quantity of
|
Noradrenaline
|
in hypothalamus
|
| 28650 |
Noradrenaline
|
|
affects_activity of
|
HPA axis
|
|
|
18191822
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,120
|
| 28651 |
high-fat diet
|
|
increases_quantity of
|
Noradrenaline
|
in the paraventricular nucleus
|
|
20212497
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,285
|
| 30222 |
Alzheimer disease
|
|
decreases_quantity of
|
Noradrenaline
|
|
| 30244 |
Noradrenaline
|
|
affects_expression of
|
ADRB1
|
(by norepinephrine (NE) depletion)
|
|
21129451
|
Alzheimer disease
|
|
4,118
|
| 42505 |
MC4R
|
|
increases_quantity of
|
Noradrenaline
|
|
| 42508 |
Noradrenaline
|
|
affects_activity of
|
microglia
|
|
| 42540 |
ACTH
|
|
increases_quantity of
|
Noradrenaline
|
in SNS ganglion neurons
|
| 42566 |
Noradrenaline
|
|
affects_activity of
|
inflammatory response
|
|
| 42567 |
Noradrenaline
|
|
decreases_activity of
|
experimental autoimmune encephalomyelitis
|
|
| 42568 |
Melanocortin
|
|
increases_quantity of
|
Noradrenaline
|
|
| 42580 |
Noradrenaline
|
|
decreases_activity of
|
microglia
|
if bound to beta2-adrenegic receptors on microglia
|
| 42581 |
locus ceruleus
|
|
affects_quantity of
|
Noradrenaline
|
in the cortex
|
|
23034287
|
Multiple sclerosis
|
|
5,013
|
| 49500 |
Noradrenaline
|
|
increases_quantity of
|
Glycerol
|
extracellular, in abdominal adipose tissue, in femoral adipose tissue
|
| 49502 |
Noradrenaline
|
|
increases_activity of
|
decreased blood flow
|
in abdominal adipose tissue, in femoral adipose tissue
|
| 49506 |
sympathetic nervous system
|
|
increases_quantity of
|
Noradrenaline
|
in blood plasma
|
|
9655773
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,317
|
| 52228 |
Noradrenaline
|
|
increases_expression of
|
PPARGC1A
|
in white adipose tissue
|
| 52229 |
Noradrenaline
|
|
increases_expression of
|
UCP1
|
in white adipose tissue
|
|
23021218
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,783
|
| 54585 |
Noradrenaline
|
|
decreases_activity of
|
insulin secretion
|
in pancreas, in pancreatic beta cells
|
|
25697093
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,393
|
| 60570 |
G6PC
|
NOT |
affects_quantity of
|
Noradrenaline
|
|
|
22013018
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,422
|
| 60530 |
recurrent sleep restriction
|
|
increases_quantity of
|
Noradrenaline
|
in a setting of high caloric intake and physical inactivity
|
|
19567526
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,523
|
| 62377 |
Noradrenaline
|
|
increases_activity of
|
abnormal vascular endothelial cell physiology
|
|
|
18177481
|
Diabetes mellitus, type II
Insulin resistance
Cardiomyopathy, diabetic
|
|
6,586
|
| 63556 |
Noradrenaline
|
|
increases_activity of
|
pineal gland
|
|
|
25623152
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,594
|
| 62939 |
Metformin
|
|
decreases_quantity of
|
Noradrenaline
|
in blood plasma; in obese, non-diabetic, hypertensive women
|
|
8269798
|
Diabetes mellitus, type II
Insulin resistance
|
|
6,663
|
| 64521 |
UGCG
|
|
affects_quantity of
|
Noradrenaline
|
|
|
26038579
|
Diabetes mellitus, type II
Insulin resistance
|
|
7,531
|
| 75236 |
Noradrenaline
|
|
decreases_activity of
|
somatostatin secretion
|
|
| 75376 |
Noradrenaline
|
|
increases_quantity of
|
Glucagon
|
in brown adipose tissue
|
|
28275047
|
Diabetes mellitus, type II
Insulin resistance
|
|
7,552
|
| 74763 |
DBH
|
|
increases_quantity of
|
Noradrenaline
|
|
| 74765 |
Dopamine
|
|
increases_quantity of
|
Noradrenaline
|
|
|
27778639
|
Neurological
|
|
7,553
|
| 74829 |
Vitiligo
|
|
increases_quantity of
|
Noradrenaline
|
in plasma and urine
|
| 74842 |
PNMT
|
|
decreases_quantity of
|
Noradrenaline
|
|
| 76106 |
Noradrenaline
|
|
increases_quantity of
|
Adrenaline
|
|
|
8204666
|
Metabolic
|
|
7,559
|
| 74864 |
Phenylketonuria
|
|
decreases_quantity of
|
Noradrenaline
|
due to high Phe concentrations in PKU patients
|
|
26425393
|
Metabolic
Phenylketonuria
|
|
8,083
|
| 80832 |
Alzheimer disease
|
|
decreases_quantity of
|
Noradrenaline
|
in csf; measured in csf by LC-ECA (USA)
|
|
28301062
|
Alzheimer disease
|
|
8,655
|
| 90938 |
rigorous exercise
|
|
increases_quantity of
|
Noradrenaline
|
in plasma; of healthy male subjects in exercise-alone experiment
|
|
16324927
|
Metabolic
|
|
9,092
|
| 96297 |
Noradrenaline
|
|
affects_activity of
|
prefrontal cortex
|
concerning optimal executive functioning and prefrontal cortex regulation of subcortical brain structures
|
| 96299 |
Estrogen
|
|
affects_activity of
|
Noradrenaline
|
in the prefrontal cortex (PFC)
|
| 96339 |
Estrogen
|
|
decreases_quantity of
|
Noradrenaline
|
in the prefrontal cortex of rats OVXed at 55 to 60 days; via increasing turnover rate of NE to MHPG
|
|
23238908
|
Developmental
Metabolic
|
|
9,171
|
| 97305 |
high-intensity exercise
|
|
increases_quantity of
|
Noradrenaline
|
in plasma
|
|
16324927
|
Metabolic
|
|
9,210
|
| 97685 |
Noradrenaline
|
|
increases_activity of
|
altered gut microbiota composition
|
resulting in the shifting of gut bacterial populations from predominantly Gram-positive to Gram-negative
|
| 97686 |
Noradrenaline
|
|
increases_quantity of
|
Gram-negative bacteria
|
resulting in the shifting of gut bacterial populations from predominantly Gram-positive to Gram-negative
|
| 97687 |
Desipramine hydrochloride
|
|
decreases_activity of
|
Noradrenaline
|
|
| 97688 |
Noradrenaline
|
|
increases_quantity of
|
Escherichia coli
|
resulting in the shifting of gut bacterial populations from predominantly Gram-positive to Gram-negative
|
|
9245571
|
Gastrointestinal
Metabolic
|
|
9,274
|
| 98845 |
response to psychosocial stress
|
|
decreases_quantity of
|
Noradrenaline
|
in brain of rat offspring separated from their mother
|
| 98857 |
Escherichia coli
|
|
increases_quantity of
|
Noradrenaline
|
|
| 98858 |
Bacillus
|
|
increases_quantity of
|
Noradrenaline
|
|
| 98859 |
Saccharomyces
|
|
increases_quantity of
|
Noradrenaline
|
|
|
26598580
|
Neurological
Gastrointestinal
Metabolic
Major depressive disorder
|
|
9,551
|
| 101283 |
VAV2
|
|
affects_quantity of
|
Noradrenaline
|
|
|
17202406
|
Cardiovascular disease
|
|
9,836
|
| 103638 |
Noradrenaline
|
|
increases_quantity of
|
CBL
|
in cardiomyocytes; of neonatal rats
|
|
24583314
|
Cardiomyopathy, dilated
|
|
9,851
|
| 103744 |
sepsis
|
|
increases_quantity of
|
Noradrenaline
|
in heart
|
|
19039652
|
Cardiovascular disease
|
CIDeRplus